IP Library › Granted Patent US 12,454,532
Granted Patent B2
US 12,454,532 · App. 18/371,647 · Granted Oct 28, 2025

Inhibiting cyclic AMP-responsive element-binding protein (CREB) binding protein (CBP)

Inventors: George Luke (Clinton, CT); Suresh Babu (Ypsilanti, MI)
Assignee: FORMA Therapeutics, Inc.
C07D471/04A61K9/1611A61K9/1617A61K9/1623A61K9/1635A61K9/1652A61K9/485A61K9/4858A61K9/4866
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,454,532
App. No.
18/371,647
Granted
Oct 28, 2025
Kind
B2
Abstract

The present disclosure is directed to solid and salt forms of inhibitors of the CBP/p300 family of bromodomains made up of salts and crystalline forms of Formula (I). The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds.

Claims (16)

1. A solid form type B of a hydrochloric acid addition salt of a compound of formula (II):

characterized by an X-ray powder diffraction pattern comprising at least three peak positions (degrees 2θ±0.2) when measured using Cu Kα radiation, selected from the group consisting of: 10.23, 18.72, 23.03, 24.77, and 28.03.

2. A method of inhibiting one or more CBP/p300-family bromodomains in a patient comprising administering to the patient in need thereof a therapeutically effective amount of the solid form of claim 1 .

3. A method of inhibiting one or more CBP/p300-family bromodomains in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the solid form of claim 1 .

4. A method of treating breast cancer in a patient comprising administering to the patient in need thereof a therapeutically effective amount of the solid form of claim 1 .

5. A method of treating breast cancer in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the solid form of claim 1 .

6. A method of treating prostate cancer in a patient comprising administering to the patient in need thereof a therapeutically effective amount of the solid form of claim 1 .

7. A method of treating prostate cancer in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the solid form of claim 1 .

8. A solid form type C of a hydrochloric acid addition salt of a compound of formula (II):

characterized by an X-ray powder diffraction pattern comprising at least three peak positions (degrees 2θ±0.2) when measured using Cu Kα radiation, selected from the group consisting of: 7.05, 19.84, 21.09, 24.98, and 31.44.

9. A method of inhibiting one or more CBP/p300-family bromodomains in a patient comprising administering to the patient in need thereof a therapeutically effective amount of the solid form of claim 8 .

10. A method of inhibiting one or more CBP/p300-family bromodomains in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the solid form of claim 8 .

11. A method of treating breast cancer in a patient comprising administering to the patient in need thereof a therapeutically effective amount of the solid form of claim 8 .

12. A method of treating breast cancer in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the solid form of claim 8 .

13. A method of treating prostate cancer in a patient comprising administering to the patient in need thereof a therapeutically effective amount of the solid form of claim 8 .

14. A method of treating prostate cancer in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the solid form of claim 8 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2025
From: LUKE, GEORGE; BABU, SURESH
To: FORMA THERAPEUTICS, INC.
Reel/Frame 071407/0342 →
Continuity (3)
Continuation 17482717 · Sep 23, 2021
Provisional Application 63082168 · Sep 23, 2020
Related Publication 20240150347A1 · May 9, 2024
References Cited (120)
US 6011029A · Ding et al. · 2000 [cited by applicant]
US 7101869B2 · Blumenkopf et al. · 2006 [cited by applicant]
US 7709489B2 · Aranyi et al. · 2010 [cited by applicant]
US 9211333B2 · Zhang · 2015 [cited by applicant]
US 9763922B2 · Adler et al. · 2017 [cited by applicant]
US 9975896B2 · Marineau et al. · 2018 [cited by applicant]
US 10336722B2 · Bair et al. · 2019 [cited by applicant]
US 10562916B2 · Campbell et al. · 2020 [cited by applicant]
US 10870648B2 · Schiller et al. · 2020 [cited by applicant]
US 11795168B2 · Luke · 2023 [cited by examiner]
US 20040214825A1 · McCall et al. · 2004 [cited by applicant]
US 20060106020A1 · Rodgers et al. · 2006 [cited by applicant]
US 20060167047A1 · Timmers et al. · 2006 [cited by applicant]
US 20070179165A1 · Gyorkos et al. · 2007 [cited by applicant]
US 20070203236A1 · Smith et al. · 2007 [cited by applicant]
US 20070254961A1 · Tapas Kumar et al. · 2007 [cited by applicant]
US 20090326020A1 · Miller et al. · 2009 [cited by applicant]
US 20100166781A1 · Setiadi et al. · 2010 [cited by applicant]
US 20100179325A1 · Suzuki et al. · 2010 [cited by applicant]
US 20100216853A1 · Marmorstein et al. · 2010 [cited by applicant]
US 20100267672A1 · Jung et al. · 2010 [cited by applicant]
US 20110257196A1 · Lu et al. · 2011 [cited by applicant]
US 20120108581A1 · Ashikawa et al. · 2012 [cited by applicant]
US 20120258953A1 · Aay et al. · 2012 [cited by applicant]
US 20130158003A1 · Campbell et al. · 2013 [cited by applicant]
US 20130324580A1 · Zhang · 2013 [cited by applicant]
US 20160158207A1 · Adler et al. · 2016 [cited by applicant]
US 20160257692A1 · Bair et al. · 2016 [cited by applicant]
US 20200216445A1 · Schiller et al. · 2020 [cited by applicant]
EP 2412710A1 · 2012 [cited by applicant]
JP 2013526615A · 2013 [cited by applicant]
JP 2016540831A · 2016 [cited by applicant]
JP 2017537100A · 2017 [cited by applicant]
WO 9520589A1 · 1995 [cited by applicant]
WO 0240614A1 · 2002 [cited by applicant]
WO 03033517A1 · 2003 [cited by applicant]
WO 03045929A1 · 2003 [cited by applicant]
WO 2004043392A2 · 2004 [cited by applicant]
WO 2005066162A1 · 2005 [cited by applicant]
WO 2007120339A1 · 2007 [cited by applicant]
WO 2007133653A2 · 2007 [cited by applicant]
WO 2008009348A1 · 2008 [cited by applicant]
WO 2009000413A1 · 2008 [cited by applicant]
WO 2009064251A1 · 2009 [cited by applicant]
WO 2009152072A1 · 2009 [cited by applicant]
WO 2010110380A1 · 2010 [cited by applicant]
WO 2010118208A1 · 2010 [cited by applicant]
WO 2010138490A1 · 2010 [cited by applicant]
WO 2011085039A2 · 2011 [cited by applicant]
WO 2011109059A1 · 2011 [cited by applicant]
WO 2011150156A2 · 2011 [cited by applicant]
WO 2012019093A1 · 2012 [cited by applicant]
WO 2012080729A2 · 2012 [cited by applicant]
WO 2012082837A1 · 2012 [cited by applicant]
WO 2012116135A2 · 2012 [cited by applicant]
WO 2013004995A1 · 2013 [cited by applicant]
WO 2013006485A1 · 2013 [cited by applicant]
WO 2013148114A1 · 2013 [cited by applicant]
WO 2014045305A1 · 2014 [cited by applicant]
WO 2014133414A2 · 2014 [cited by applicant]
WO 2014182929A1 · 2014 [cited by applicant]
WO 2015002754A2 · 2015 [cited by applicant]
WO 2015004533A2 · 2015 [cited by applicant]
WO 2015013635A2 · 2015 [cited by applicant]
WO 2015022322A1 · 2015 [cited by applicant]
WO 2015073763A1 · 2015 [cited by applicant]
WO 2015074064A2 · 2015 [cited by applicant]
WO 2015074081A1 · 2015 [cited by applicant]
WO 2016044694A1 · 2016 [cited by applicant]
WO 2016086200A1 · 2016 [cited by applicant]
WO 2016110821A1 · 2016 [cited by applicant]
WO 2016128908A1 · 2016 [cited by applicant]
WO 2016170323A1 · 2016 [cited by applicant]
WO 2016170324A1 · 2016 [cited by applicant]
WO 2017197056A1 · 2017 [cited by applicant]
WO 2017197240A1 · 2017 [cited by applicant]
WO 2017205536A2 · 2017 [cited by applicant]
WO 2018073586A1 · 2018 [cited by applicant]
WO 2018073587A1 · 2018 [cited by applicant]
WO 2019055869A1 · 2019 [cited by applicant]
WO 2019055877A1 · 2019 [cited by applicant]
WO 2020006483A1 · 2020 [cited by applicant]
WO 2020190780A1 · 2020 [cited by applicant]
Stahl et al., International Union of pure and applied chemistry, pharmaceutical salts, pp. 250-253. [cited by examiner]
Bowers E.M., et al., “Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Indentification of a Selective Small Molecule Inhibitor,” Chemistry Biology, May 28, 2020, vol. 17, pp. 471-482. [cited by applicant]
Carpizo V., et al., “CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR Positive breast Cancer Cell Lines,” Molecular Cancer Research, 2019, vol. 17, No. 3, pp. 1-27. [cited by applicant]
Chekler E.L.P., et al., “Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities,” Chemistry and Biology, Dec. 17, 2015, vol. 22, No. 12, 1588-1596. [cited by applicant]
Crawford T.D., et al., “Discovery of a Potent and Selective Vivo Probe (GNE-272) for the Bromodomains to CBP/EP300,” Journal of Medicinal Chemistry, Sep. 22, 2016, 56 pages. [cited by applicant]
Depmap Portal, “AR: Anderson Receptor,” Depmap portal, [Retrieved on May 28, 2020], (release 19Q2V), 2 pages, Retrieved from the Internet: URL: https://depmap.org/portal/gene/AR?tab=characterization. [cited by applicant]
Extended European Search Report for European Application No. EP19183741.8, mailed on Aug. 1, 2019, 8 pages. [cited by applicant]
Extended European Search Report for European Application No. EP20773477.3, mailed on Nov. 29, 2022, 6 pages. [cited by applicant]
Fan S., et al., “p300 Modulates the BRCA1 Inhibition of Estrogen Receptor Activity,” Cancer Research, Jan. 1, 2002, vol. 62 , No. 1, pp. 141-151. [cited by applicant]
Goff C., et al., “Synthesis of Some Novel Fused Tetracyclic Quinolonecarboxylic Acids Via 7-Methyl-6,7,8,9-Tetrahydro-3H-Imidazo[4,5-f]Quinoline and 6-Methyl-5,6,7,8-Tetrahydro-1H-Imidazo[4,5-g]Quinoline,” Journal of He… [cited by applicant]
Hammitzach A., et al., “CBP30, A Selective CBP/p300 Bromodomain Inhibitor, Suppresses Human Th 17 Responses,” Proceedings of the National Academy of Science, Aug. 25, 2015, vol. 112, No. 34, pp. 10768-10773. [cited by applicant]
Hay D., A., et al., “Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains,” Journal of the American Chemical Society, Jun. 19, 2014, vol. 136, No. 26, pp. 9308-9319. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2019/039936, mailed on Sep. 23, 2019, 12 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2020/022783 , mailed on Jun. 10, 2020, 6 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2020/022818, mailed on Jun. 15, 2020, 7 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2020/022823 , mailed on Jun. 15, 2020, 7 pages. [cited by applicant]
International Search Report for Application No. PCT/US2017/034320, mailed on Nov. 15, 2017, 10 pages. [cited by applicant]
International Search Report for Application No. PCT/US2018/051214, mailed on Dec. 4, 2018, 4 pages. [cited by applicant]
International Search Report for Application No. PCT/US2018/051235, mailed on Feb. 25, 2019, 3 pages. [cited by applicant]
International Search Report for Application No. PCT/US2014/066198, Mailed on May 18, 2015, 4 pages. [cited by applicant]
Jiang M., et al., “Small Molecule nAS-E Targeting Camp Response Element Binding Protein (CREB) And CREB-Binding Protein Interaction Inhibits Breast Cancer Bone Metastasis,” Journal of Cellular and Molecular Medicine, Fe… [cited by applicant]
Jin L., et al., “Therapeutic Targeting of the CRP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer,” Cancer Research, Oct. 15, 2017, vol. 77, No. 20, pp. 5564-5575. [cited by applicant]
Kumar V., et al., “Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer,” JCO Precision Oncology, Oct. 10, 2017, vol. 01… [cited by applicant]
Lasko L.M., et al., “Discovery of a Selective Catalytic P300/CBP Inhibitor that Targets Lineage-Specific Tumours,” Nature, Sep. 27, 2017, vol. 000, 17 pages. [cited by applicant]
Liberson A., et al., “Gene Set: Hallmark_Androgen_Response,” Gene Set Enrichment Analysis, [Retrieved on May 28, 2020], 1 page. [cited by applicant]
Moustakim M., et al., “Discovery of a PCAF Bromodomain Chemical Probe,” Angewandte Chemie, Dec. 14, 2016, vol. 129, No. 3, pp. 845-849. [cited by applicant]
Pubchem, “(1R,3R)-3-[(7S)-2-[(5-Fluoro-2-methoxyphenyl)-hydroxymethyl]-6-methoxycarbonyl-7-methyl-8,9-dihydro-7H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid,” Pubchem CID: 138472436, Aug. 20, 2019, 8 pages. [cited by applicant]
Pubchem, “Tert-butyl 3,7,8,9-tetrahydroimidazo [4,5- f]quinoline-6-carboxylate,” PubChem CID: 136574372, Jan. 24, 2019, 8 pages. [cited by applicant]
Robinson J.L.L., et al., “Androgen Receptor Driven Transcription in Molecular Apocrine Breast Cancer is Mediated by FoxA1,” The EMBO Journal, Jun. 24, 2011, vol. 30, No. 15, pp. 3019-3027. [cited by applicant]
Safarpour D., et al., “Androgen Receptor (AR) Expression in 400 Breast Carcinomas: Is Routine AR Assessment Justified,” American Journal of Cancer Research, Jul. 30, 2014, vol. 04, No. 04, pp. 353-368. [cited by applicant]
Scher H.I., et al., “Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker with Outcomes and Survival in Castration-Resistant Prostate Cancer,” JAMA Oncology, Nov. 10, 2016, vol. 02, No. 11, … [cited by applicant]
Snow R., et al., “Discovery of 2-Phenylamino-Imidazo[4-5-h]Isoquinolin-9-ones: a New Class of Inhibitors f Lck Kinase,” Journal of Medicinal Chemistry, Mar. 11, 2002, vol. 45, pp. 3394-3405. [cited by applicant]
Solankee A., et al., “Synthesis and Evaluation of Some Novel S-Triazine Based Chalcones and their Derivatives,” Der Pharma Chemica, 2011 , vol. 3 , No. 6 , pp. 317-324. [cited by applicant]
Sucher H., et al., “Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer,” JAMA Oncology, Sep. … [cited by applicant]
Traina T.A., et al., “Enzalutamide for the Treatment of Androgen Receptor—Expressing Triple-Negative Breast Cancer, ”Journal of Clinical Oncology, Mar. 20, 2018, vol. 36, No. 9, pp. 884-890. [cited by applicant]
Tucci M., et al., “Enzalutamide-Resistant Castration-Resistant Prostate Cancer: Challenges and Solutions,” Onco Targets and Therapy, Oct. 2018, vol. 11, pp. 7353-7368. [cited by applicant]
Wong H., et al., “Anti-Tumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response,” Clinical Cancer Research, May 30, 2016, vol. 18, No. 14, pp. 1-36. [cited by applicant]